Get the Stockscreener App
27.68
0.95%
0.26
After Hours:
27.83
0.15
+0.54%
Maze Therapeutics Inc stock is traded at $27.68, with a volume of 2.45M.
It is up +0.95% in the last 24 hours and down -44.87% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$27.42
Open:
$27.66
24h Volume:
2.45M
Relative Volume:
3.18
Market Cap:
$1.38B
Revenue:
$2.50M
Net Income/Loss:
$-131.12M
P/E Ratio:
-9.7359
EPS:
-2.8431
Net Cash Flow:
$-112.73M
1W Performance:
-2.29%
1M Performance:
-44.87%
6M Performance:
-2.88%
1Y Performance:
+225.65%
1-Day Range:
$27.10
$28.72
1-Week Range:
$26.16
$29.50
52-Week Range:
$7.16
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
27.68 | 1.33B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-10-26 | Initiated | Mizuho | Outperform |
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
View All
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN
Maze Therapeutics Inc. places pharma partnerships in focus as President of R and D moderates Boston panel - Traders Union
What analysts say about Maze Therapeutics Inc stockWeekly Gains Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
MAZE Options Volatility — NASDAQ:MAZE - TradingView — Track All Markets
MAZE Options Chain — NASDAQ:MAZE - TradingView — Track All Markets
MAZE News Today | Why did Maze Therapeutics stock go up today? - MarketBeat
Gainers Report: Is CLVT a play on infrastructure spending2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks - Sahm
Rally Mode: Whats the fair value of Maze Therapeutics Inc stockWeekly Loss Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial - Streetwise Reports
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks - Insider Monkey
Pharma News: What analysts say about Maze Therapeutics Inc stock2026 Review & Daily Stock Momentum Reports - baoquankhu1.vn
8 Most Oversold Strong Buy-Rated Stocks to Invest In - Insider Monkey
Does Maze Therapeutics Inc have declining or rising EPS2026 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - Yahoo Finance
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock - MarketBeat
Maze Therapeutics (MAZE) executive exercises options and sells 15,000 shares - Stock Titan
Maze Therapeutics (MAZE) SVP sells 2,500 shares after option exercise - Stock Titan
Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE - marketbeat.com
Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock By Investing.com - Investing.com South Africa
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock - Investing.com Canada
Maze Therapeutics (MAZE) CSBO exercises options and sells 7,500 shares - Stock Titan
Paradigm group holds 6.1% of Maze Therapeutics (NASDAQ: MAZE) in Schedule 13G - Stock Titan
Director at Maze (NASDAQ: MAZE) receives 33,417 stock options grant - Stock Titan
Maze Therapeutics (MAZE) director Neil Kumar submits initial Form 3 - Stock Titan
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00 - MarketBeat
Proposed 30,000-share option exercise by MAZE (NASDAQ: MAZE) reported - Stock Titan
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital - The Globe and Mail
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
Support Test: Is Maze Therapeutics Inc forming bullish engulfing patterns2026 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE) - Seeking Alpha
After a 30.8% Drop Over the Past Four Weeks, Here’s What Could Cause Maze Therapeutics, Inc. (MAZE) to Rebound - Bitget
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - Yahoo Finance
Q1 EPS Forecast for Maze Therapeutics Raised by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF) - The Globe and Mail
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Sahm
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829 - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat - marketbeat.com
MAZE Shareholders Are Encouraged to Reach Out to Johnson - GlobeNewswire
Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright - Defense World
Maze Therapeutics 2025 Annual Report: Pipeline, Strategy, and Clinical Program Overview - Minichart
Decoding Maze Therapeutics Inc (MAZE): A Strategic SWOT Insight - GuruFocus
Maze Therapeutics Executive Sells All Shares Ahead of Q4 Earnings Report - Intellectia AI
Maze Therapeutics Inc Stock (MAZE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):